600 Participants Needed

CBT + Trazodone for Insomnia

Recruiting at 4 trial locations
CC
Overseen ByCarrie Criley
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Milton S. Hershey Medical Center
Must be taking: Antihypertensives

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how two common treatments for insomnia work for people with different sleep patterns. Participants with chronic insomnia will first try Cognitive Behavioral Therapy for Insomnia (CBT-I), a type of talk therapy. If CBT-I proves ineffective, they will receive either trazodone, a non-addictive sleep medication, or a placebo. The trial aims to determine if individuals with short or normal sleep durations respond differently to these treatments. Those with chronic insomnia and a BMI of 18.5 or higher might be suitable candidates. As an Early Phase 1 trial, this research focuses on understanding how these treatments work in people, offering participants a chance to contribute to foundational insomnia research.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop all current medications, but you cannot use medications for sleep more than twice a week, systemic corticosteroids, opiates, or any medications that don't mix well with trazodone. You must also continue your anti-hypertensive medication if you're on it.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that both treatments in this study are safe. Cognitive Behavioral Therapy for Insomnia (CBT-I) is a safe and effective method, with studies indicating long-lasting benefits and very few risks. Since it doesn't involve medication, there are no drug-related side effects.

Trazodone, used in a low dose for insomnia, is a commonly prescribed medication that is not addictive. Research has found that it can greatly improve sleep time without causing major side effects. However, like any medication, some people might experience mild side effects such as dizziness or a dry mouth.

Overall, both treatments are generally well-tolerated, with trazodone having a few possible mild side effects.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about combining Cognitive Behavioral Treatment for Insomnia (CBT-I) with trazodone because it offers a unique two-step approach to treating insomnia. While most treatments focus solely on either behavioral therapy or medication, this method starts with CBT-I, a well-established therapy that addresses the root causes of insomnia. If patients don't respond fully, trazodone, an antidepressant with sedative effects, is added to enhance sleep quality. This combination could offer a more comprehensive solution by tackling both psychological and physiological aspects of insomnia, potentially leading to better outcomes than current options like sleep medications or CBT-I alone.

What evidence suggests that this trial's treatments could be effective for insomnia?

Research shows that trazodone can help people with insomnia sleep longer, particularly those who typically sleep for a short duration. Trazodone also lowers blood pressure and reduces evening cortisol levels, a hormone related to stress. In this trial, some participants will receive Cognitive Behavioral Therapy for Insomnia (CBT-I) with trazodone. Conversely, CBT-I works well for individuals with insomnia who already sleep a normal amount, showing about a 30% higher success rate for this group. Other participants in this trial will receive CBT-I with a placebo. Both treatments effectively address long-term insomnia and have few side effects. These findings suggest that both trazodone and CBT-I can be helpful, but their success may depend on the type of insomnia present.13678

Who Is on the Research Team?

AV

Alexandros Vgontzas, MD

Principal Investigator

Professor, Psychiatry

Are You a Good Fit for This Trial?

This trial is for adults with chronic insomnia, particularly those who sleep less than normal (ISS) or have a normal sleep duration (INS), and also have high blood pressure. Participants should not be currently using other treatments for insomnia.

Inclusion Criteria

Body Mass Index (BMI) 18.5-<40 kg/m2
I can read and communicate effectively in English or French (in Canada).
I have been diagnosed with chronic insomnia.
See 1 more

Exclusion Criteria

I am not willing to share my contact details for surveys.
Unstable medical conditions that would make participation unsafe or unfeasible
I am under 18 years old.
See 20 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks. Non-remitting subjects then receive either trazodone or placebo for an additional 8 weeks.

16 weeks

Follow-up

Participants are monitored for remission of insomnia symptoms and other secondary outcomes such as cortisol levels and blood pressure.

35 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Cognitive Behavioral Treatment for Insomnia (CBT-I)
  • Placebo
  • Trazodone
Trial Overview The study tests Cognitive Behavioral Therapy for Insomnia (CBT-I), which is a non-drug treatment focusing on changing sleep habits, versus Trazodone, a low-dose medication that helps with sleep without forming habits. The effectiveness of these treatments will be compared.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with TrazodoneActive Control2 Interventions
Group II: Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with placeboPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Milton S. Hershey Medical Center

Lead Sponsor

Trials
515
Recruited
2,873,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

Cognitive behavioral therapy for insomnia (CBT-I) is recognized as the first-line treatment for both uncomplicated insomnia and insomnia associated with other chronic disorders, demonstrating its broad efficacy.
This review aims to summarize efficacy data across various clinical and demographic factors and to outline future research and implementation strategies for CBT-I, highlighting its importance in treating sleep disorders.
We know CBT-I works, now what?Muench, A., Vargas, I., Grandner, MA., et al.[2022]
Cognitive Behavioral Therapy for insomnia (CBT-i) is an effective first-line treatment for chronic insomnia, showing significant improvements in sleep onset latency (SOL) by about 19 minutes and wake after sleep onset (WASO) by about 26 minutes based on a review of 20 studies involving 1162 participants.
The benefits of CBT-i, which includes techniques like cognitive therapy and sleep hygiene, appear to be sustained over time, and importantly, no adverse effects were reported, making it a safe alternative to pharmacological treatments.
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.Trauer, JM., Qian, MY., Doyle, JS., et al.[2022]
Cognitive-behavioral therapy for insomnia (CBT-I) showed positive effects on sleep quality and depressive symptoms in a study of 30 psychiatric outpatients, with 38% achieving normal sleep after treatment.
While CBT-I led to significant improvements within the treatment group over 4 and 8 weeks, there were no significant differences when compared to the control group, suggesting that while beneficial, the effects may not be strong enough to outperform standard care alone.
Effectiveness of abbreviated CBT for insomnia in psychiatric outpatients: sleep and depression outcomes.Wagley, JN., Rybarczyk, B., Nay, WT., et al.[2022]

Citations

Effects of trazodone versus cognitive behavioral therapy in ...The current preliminary, open-label, randomized trial suggests that trazodone, but not CBT-I, significantly improves objective sleep duration.
NCT04468776 | CBT-I or Zolpidem/Trazodone for InsomniaThis study is a randomized (1:1:1) comparative effectiveness trial of medication (zolpidem or trazodone), cognitive-behavioral therapy for insomnia (CBT-I), ...
0540 Comparative Effectiveness of Medication, Digital CBT-I ...Side effects were minimal in all groups. All three treatments showed robust effectiveness for chronic insomnia in primary care practices.
1/2 Cognitive Behavioral Therapy and Trazodone Effects ...Trazodone, but not CBT-I, increases objective total sleep time (TST), and lowers BP and evening cortisol in ISS.
Cognitive-behavioral therapy for insomnia with objective ...The main outcome was that CBT-I had a better efficacy for the INS phenotype compared with the ISS phenotype, with about 30% higher response and about 20% ...
Cognitive Behavioral Therapy and Trazodone Effects on ...This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive ...
A randomized controlled trial of a digital cognitive ...Meta-analyses support CBT-I as efficacious and safe, with long-lasting effects in older adults. As a behavioral rather than pharmacological ...
Cognitive Behavioral Therapy for Insomnia (CBT-I): A PrimerCBT-I is a multi-component treatment for insomnia that targets difficulties with initiating and/or maintaining sleep and is delivered over the course of six to ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security